ER (Estrogen receptor)

P2, N=60, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Apr 2026 --> Apr 2027

P1, N=60, Recruiting, Immunomic Therapeutics, Inc.

To our knowledge, this is the first comprehensive MR study linking sex hormone-related factors (E2, EST, BCAR3) to increased oral cavity cancer risk. Further validation is needed to explore prevention and treatment implications.

HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.

We developed and validated a well-calibrated nomogram for predicting DFS in patients with HR+/HER- breast cancer. This nomogram uniquely integrates MHR with clinicopathological factors to predict prognosis in HR+/HER2- breast cancer and can facilitate individualized therapeutic planning.

Obesity was associated with lower ORR with letrozole alone, whereas this association was not observed in patients treated with taselisib.

Postoperatively, he received adjuvant stereotactic radiosurgery (30-35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T-DXd) for improved CNS-directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS-penetrant HER2-targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.

Although anti-estrogen treatments such as tamoxifen have significantly improved treatment outcomes, but their prolonged use is associated with therapeutic resistance and adverse effects...The multistep screening identified HIT 1 compound with a superior docking score (-13.901 kcal/mol) as compared to standard drug raloxifene (-12.136 kcal/mol), as well as favourable pharmacokinetic properties and enhanced MM-GBSA binding free energies...In addition, DFT calculations supported its electronic stability and bio-feasibility through analysing its HOMO-LUMO energy gap. These results suggest that the HIT 1 molecule serves as a promising scaffold for the development of a novel ERα modulator with potential to suppress ERα-mediated BC progression and angiogenesis.

These results demonstrate that both dPCR and NGS-based liquid biopsy workflows can be successfully implemented for ESR1 mutation testing in routine clinical practice using locally validated assays. This multicentre verification study provides practical guidance on assay verification, DNA input requirements, and key analytical parameters required to ensure reliable ESR1 mutation detection across different European laboratories. Robust analytical verification of ESR1 testing may improve diagnostic reliability and support personalized treatment strategies for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

A transcriptional signature associated with SARM sensitivity was identified, primarily driven by proliferation-related processes, consistent with a significant decrease in S-phase cell cycle proteins upon treatment in EP0062-sensitive models. In some EP0062-resistant tumors, the combination with palbociclib enhanced the antitumor effect of EP0062, suggesting a potential strategy for metastatic patients with acquired ET resistance.

68Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18F-FDG, particularly in hormone-receptor-positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.

The need for chemotherapy in postmenopausal HR + , HER2- breast cancer patients might be further informed by integrating the results of the Oncotype DX test with the response to NET.